A Product overview with focus on Rare Diseases.
AOP Orphan's focus is on Rare Diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.
Following products are currently available in the UK.
Adepend is used as part of a comprehensive programme of treatment against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
Anagrelide AOP is used to reduce the number of platelets in patients with essential thrombocythaemia.
Argipressin AOP is used to treat diabetes insipidus and bleeding from enlarged veins in the oesophagus.
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.
Esmolol® is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.
Naloxone hydrochloride is for complete or partial reversal of CNS and especially respiratory depression, caused by natural or synthetic opioids.
Naltrexone AOP is for use as an additional therapy within a comprehensive treatment program including psychological guidance for detoxified patients who have been opioid-dependent.
Tardiben tablets are indicated for both hyperkinetic motor disorders associated with Huntington’s chorea and the treatment of moderate to severe tardive dyskinesia, which is an adverse effect associated with antipsychotic medicines.
Tetrabenazine is used for the treatment of diseases causing jerky, irregular, uncontrollable movements (hyperkinetic motor disorders with Huntington’s chorea).